Payment overview · 2025
General Payments
$49.29
3 reported records · 3 companies
Healthcare provider profile · identity verified
Randall P Leduc, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AURORA, IN · NPI 1912053067
Verified facts
What the public records show
CMS Open Payments records show Randall P Leduc, MD received $49.29 in general payments during 2025 across 3 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.54 | 39.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.46 | 31.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.29 | 29.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.29 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 930 | 259 |
| Levothyroxine Sodium | Levothyroxine Sodium | 447 | 103 |
| Montelukast Sodium | Montelukast Sodium | 417 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 391 | 108 |
| Lisinopril | Lisinopril | 350 | 96 |
| Gabapentin | Gabapentin | 338 | 75 |
| Omeprazole | Omeprazole | 297 | 73 |
| Ipratropium Bromide | Ipratropium Bromide | 285 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 79 |
| Furosemide | Furosemide | 262 | 79 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 252 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 65 |
| Prednisone | Prednisone | 227 | 145 |
| Losartan Potassium | Losartan Potassium | 215 | 62 |
| Sertraline Hcl | Sertraline Hcl | 199 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 67 |
| Metformin Hcl | Metformin Hcl | 182 | 49 |
| Amoxicillin | Amoxicillin | 181 | 132 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 38 |
| Atenolol | Atenolol | 165 | 41 |
| Chlorthalidone | Chlorthalidone | 162 | 47 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 160 | 26 |
| Glipizide | Glipizide | 159 | 44 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 156 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 34 |
| Finasteride | Finasteride | 137 | 33 |
| Potassium Chloride | Potassium Chloride | 136 | 39 |
| Alendronate Sodium | Alendronate Sodium | 133 | 31 |
| Allopurinol | Allopurinol | 131 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 39 |
| Enalapril Maleate | Enalapril Maleate | 125 | 30 |
| Alprazolam | Alprazolam | 124 | 34 |
| Metformin Hcl Er | Metformin Hcl | 110 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 32 |
| Ibuprofen | Ibuprofen | 99 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 96 | 19 |
| Carvedilol | Carvedilol | 94 | 26 |
| Farxiga | Dapagliflozin Propanediol | 93 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 87 | 28 |
| Meloxicam | Meloxicam | 87 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 18 |
| Ozempic | Semaglutide | 78 | 27 |
| Eliquis | Apixaban | 77 | 18 |
| Ezetimibe | Ezetimibe | 77 | 21 |
| Trulicity | Dulaglutide | 76 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 22 |
| Memantine Hcl | Memantine Hcl | 73 | 21 |
| Methotrexate | Methotrexate Sodium | 71 | 13 |
| Mirtazapine | Mirtazapine | 70 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 19 |
| Spironolactone | Spironolactone | 69 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 17 |
| Lovastatin | Lovastatin | 65 | 11 |
| Simvastatin | Simvastatin | 65 | 16 |
| Tramadol Hcl | Tramadol Hcl | 63 | 19 |
| Trazodone Hcl | Trazodone Hcl | 63 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 60 | 20 |
| Levofloxacin | Levofloxacin | 59 | 44 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 18 |
| Baclofen | Baclofen | 56 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Nabumetone | Nabumetone | 43 | 16 |
| Famotidine | Famotidine | 41 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 11 |
| Clonidine Hcl | Clonidine Hcl | 38 | 13 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Topiramate | Topiramate | 35 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Silodosin | Silodosin | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Lidocaine | Lidocaine | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 13 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.29 · 3 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, NURTEC ODT, Ozempic, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error